Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket Nos. FDA-2023-D-3132, FDA-2023-D-3133, and FDA-2023-D-3134]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice of availability.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of three draft guidances entitled “Evidentiary Expectations for 510(k) Implant Devices,” “Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions,” and “Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission.” FDA is issuing these guidances to improve the predictability, consistency, and transparency of the 510(k) premarket review process. The draft guidances are not final nor are they for implementation at this time.
 DATES: Submit either electronic or written comments on the draft guidance by December 6, 2023 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
 ADDRESSES: You may submit comments on any guidance at any time as follows: Electronic Submissions Submit electronic comments in the following way: *Federal eRulemaking Portal: https://www.regulations.gov.*
                     Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to 
                    *https://www.regulations.gov*
                     will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on 
                    *https://www.regulations.gov.*
If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”). Written/Paper Submissions Submit written/paper submissions as follows: *Mail/Hand delivery/Courier (for written/paper submissions):*
                     Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.” *Instructions:*
                     All submissions received must include Docket No. FDA-2023-D-3132 for “Evidentiary Expectations for 510(k) Implant Devices,” Docket No. FDA-2023-D-3133 for “Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions,” or Docket No. FDA-2023-D-3134 for “Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at 
                    *https://www.regulations.gov*
                     or at the Dockets Management Staff 
                    ( print page 61601)
                    between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500. Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on*https://www.regulations.gov.*
                     Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: 
                    *https://www.govinfo.gov/​content/​pkg/​FR-2015-09-18/​pdf/​2015-23389.pdf.* *Docket:*
                     For access to the docket to read background documents or the electronic and written/paper comments received, go to 
                    *https://www.regulations.gov*
                     and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). An electronic copy of the guidance document is available for download from the internet. See the 
                    **SUPPLEMENTARY INFORMATION**
                     section for information on electronic access to the guidance. Submit written requests for a single hard copy of the draft guidance document entitled “Evidentiary Expectations for 510(k) Implant Devices,” “Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions,” or “Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission” to the Office of Policy, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your request.
 FOR FURTHER INFORMATION CONTACT: Angela DeMarco, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 2436, Silver Spring, MD 20993-0002, 301-796-4471; or Anne Taylor, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7242, Silver Spring, MD 20993, 240-402-8113.


SUPPLEMENTARY INFORMATION:  I. Background As part of FDA's Medical Device Safety Action Plan: Protecting Patients, Promoting Public Health,[1]
                    
                     FDA committed to strengthen and modernize the premarket notification (510(k)) Program. FDA is issuing these three draft guidances to enhance the transparency, consistency, and predictability of the 510(k) premarket review process. In “Evidentiary Expectations for 510(k) Implant Devices,” FDA discusses considerations that are generally relevant to all types of implants subject to 510(k) requirements. This draft guidance is intended to serve as a primary resource, used in conjunction with other guidances, to provide clarity and facilitate discussions regarding expectations for performance data that may be necessary to establish substantial equivalence for implanted medical devices. However, the type and quantity of performance data needed to support a substantial equivalence determination for a particular device will vary depending on the device and/or device type and on the differences from the predicate device. In “Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions,” FDA clarifies and provides additional context for situations when clinical data may be necessary to demonstrate substantial equivalence, as initially described in the final guidance “The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]” [2]
                    
                     (“510(k) Program Guidance”). This draft guidance expands on the scenarios described in the 510(k) Program Guidance, describes another scenario, and provides additional examples to illustrate when clinical data may or may not be necessary to include in a 510(k) submission to demonstrate substantial equivalence. Finally, in “Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission,” FDA proposes four best practices for choosing a predicate device used to support a 510(k) submission. Initially, FDA considered making public on its website those cleared devices that demonstrated substantial equivalence to older predicate devices. FDA also considered focusing on predicates that were more than 10 years old as a starting point. FDA issued a public notice on its website that requested public comment on this proposal.[3]
                    
                     After considering the docket comments, FDA believes use of best practices that encourage the use of predicate devices with certain characteristics, rather than focusing on the age of the predicate, will support modernization of the 510(k) Program with respect to the use of predicate devices and encourage the evolution of safer and more effective medical devices. These draft guidances are being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidances, when finalized, will represent the current thinking of FDA on the topics discussed in “Evidentiary Expectations for 510(k) Implant Devices,” “Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions,” and “Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission.” These draft guidances do not establish any rights for any person and are not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. II. Electronic Access Persons interested in obtaining copies of these draft guidances may do so by downloading electronic copies from the internet. A search capability for all Center for Devices and Radiological Health guidance documents is available at 
                    *https://www.fda.gov/​medical-devices/​device-advice-comprehensive-
                        ( print page 61602)
                        regulatory-assistance/​guidance-documents-medical-devices-and-radiation-emitting-products*. These guidance documents are also available at 
                    *https://www.regulations.gov, https://www.fda.gov/​regulatory-information/​search-fda-guidance-documents,*
                     or 
                    *https://www.fda.gov/​vaccines-blood-biologics/​guidance-compliance-regulatory-information-biologics*. Persons unable to download an electronic copy of “Evidentiary Expectations for 510(k) Implant Devices” (document number GUI00020017), “Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions” (document number GUI00020016), or “Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission” (document number GUI00020006) may send an email request to 
                    *CDRH-Guidance@fda.hhs.gov*
                     to receive an electronic copy of the document. Please use the document number and complete title to identify the guidance you are requesting. III. Paperwork Reduction Act of 1995 While these guidances contain no new collection of information, they do refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information in the following table have been approved by OMB: 21 CFR part; guidance; or FDA form
Topic
OMB control No.807, subpart E
Premarket notification
0910-0120“Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program”
Q-Submissions and Early Payor Feedback Request Programs for Medical Devices
0910-0756800, 801, 809, and 830
Medical Device Labeling Regulations; Unique Device Identification
0910-0485803
Medical Devices; Medical Device Reporting; Manufacturer reporting, importer reporting, user facility reporting, distributor reporting
0910-0437810
Medical Device Recalls
0910-0432820
Current Good Manufacturing Practice (CGMP); Quality System (QS) Regulation
0910-0073822
Postmarket Surveillance of Medical Devices
0910-0449Forms FDA 3500 and FDA 3500A
Medical device adverse event reporting—MedWatch
0910-029158
Good Laboratory Practice (GLP) Regulations for Nonclinical Laboratory Studies
0910-0119
 Dated: September 1, 2023. Lauren K. Roth, Associate Commissioner for Policy.


# Footnotes

1.
    
                         Available at 
                        *https://www.fda.gov/​about-fda/​cdrh-reports/​medical-device-safety-action-plan-protecting-patients-promoting-public-health.* Back to Citation
 2.
    
                         Available at 
                        *https://www.fda.gov/​regulatory-information/​search-fda-guidance-documents/​510k-program-evaluating-substantial-equivalence-premarket-notifications-510k*. Back to Citation
 3.
    
                         Available at 
                        *https://wayback.archive-it.org/​7993/​20190206202131/​https://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofMedicalProductsandTobacco/​CDRH/​CDRHReports/​ucm604500.htm*. Public comments submitted can be searched under the docket FDA-2018-N-4751, available at 
                        *https://www.regulations.gov/​docket/​FDA-2018-N-4751*. Back to Citation


[FR Doc. 2023-19283 Filed 9-6-23; 8:45 am] BILLING CODE 4164-01-P